 Home > Active Ingredient News > Study of Nervous System > Expand your territory again! Alnylam RNAi therapy is approved for marketing in Europe

Expand your territory again! Alnylam RNAi therapy is approved for marketing in Europe

 Last Update: 2022-10-01
 Source: Internet
 Author: User

Tags

acquisition press release

canavan disease symptoms

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 13 of this year, Amvuttra was the first to be approved by the FDA for marketing in the United States, which is the fifth RNAi therapy

In addition, Alnylam also has a number of RNAi drugs in the clinical or preclinical stage, and its pipeline layout is involved in neuropathy, cardiovascular disease, metabolic disease and other fields

Recommended reading: Alnylam's RNAi field "throne" consolidation battle, is it the next to be approved?

brief summary

At present, Alnylam is firmly in the "throne" of the RNAi field, including the 5 RNAi drugs

In the future, we expect that RNAi therapy will bring new treatment options to more patients, and we also expect that more "Alnylam" companies will be produced

Resources:

▼September 22, Efficient synthesis strategy and process flow analysis of oligonucleotide drugs

▼On September 21, Merck China Biosafety Testing Center was opened

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium bromide airuike

CAS No.: 7647-15-6

Industrial Grade

$10/KG EXW

Brivaracetam357336-20-0

CAS No.: 357336-20-0

API Grade

$100/KG EXW

Quetiapine fumarate CAS 111974-72-2

CAS No.: 111974-72-2

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.